EPIDAREX IS A TRANSATLANTIC VENTURE CAPITAL FIRM LED BY A DIVERSE TEAM OF EARLY-STAGE INVESTORS BUILDING BREAKTHROUGH LIFE SCIENCE COMPANIES IN EMERGING HUBS
We are trusted partners to our founders and co-investors. We use our deep scientific and industry networks to create exceptional value and shared success.
Epidarex builds the extraordinary.
Recent News
Mironid successfully doses initial cohorts in Phase 1 clinical trial investigating the Company’s first-in-class LoAc® small molecule for patients with ADPKD
Glasgow, Scotland, October 1, 2026 – Mironid, a biopharmaceutical company developing small molecule therapeutics for the treatment of Autosomal Dominant Polycystic Kidney Disease
Rezera Announces Late-Breaking Presentation of RESOLVE-1 Clinical Data at the American Heart Association (AHA) Scientific Sessions 2026
Boston, MA, September 23, 2026 – Rezera Inc. (the “Company”), a clinical-stage biotechnology company developing a portfolio of internally-invented and wholly-owned oral inhibitors